Jounce Therapeutics Appoints CFO
This article was originally published in Scrip
Jounce Therapeutics Inc., a company focused on novel cancer immunotherapies, has named Kim Drapkin chief financial officer (CFO). Before joining Jounce, Drapkin was the interim CFO for various biotech companies, including Jounce, through a financial consulting firm she owned. Prior to this she was CFO at EPIX pharmaceuticals and also spent 10 years at Millennium Pharmaceuticals in roles within the finance organisation.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.